Inbrija
Manufacturing · North Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
6601 Six Forks Rd Ste 430, Raleigh, Nort...Website
www.inbrija.comRevenue
<$5 MillionIndustry
About Inbrija
Is Inbrija your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Inbrija recently announced quarterly report
Product Launch: Get notified when Inbrija launches new products
Click to see if Inbrija had a recent Job posting/layoffs
Check out if Inbrija is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Inbrija
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Inbrija, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Inbrija has new funding data
Website visits: Recent activity has been detected on your website
Check if Inbrija has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Inbrija as Masked Content
Find more new buyers
Compare Similar Companies to Inbrija
Compare insights from companies similar to Inbrija, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Inbrija
Inbrija Tech Stack
A closer look at the technologies used by Inbrija
Inbrija News & Media
INBRIJA: A Dry Powder Formulation of Levodopa for Oral Inhalation with Inhaler - Market Size, Forecast, and Market Insights for 7MM 2019-2032
Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "INBRIJA Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about INBRIJA for Parkinson's disease in the seven major markets. A detailed picture of the INBRIJA for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is providedAcorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The FightersTM”Esteve Launches INBRIJA® in Germany
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Esteve Pharmaceuticals GmbH has launched INBRIJA® 33 mg (levodopa inhalation powder, hard capsules) in Germany. INBRIJA is indicated in the EU for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibitor. (1) Under the terms of the distribution and supply agreements, Acorda will receive a
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Inbrija
Learn about INBRIJA, Prescription Support Services, and downloadable resources. Watch a video about a person who uses INBRIJA. Sign up to receive updates about the product and watch the demonstration video. See Indication, Important Safety Information, and Patient Information Leaflet.... Read More